KD025 Is a Casein Kinase 2 Inhibitor That Protects Against Glucolipotoxicity in β-Cells

Overview

Journal Diabetes

Specialty Endocrinology

Date 2024 Jan 11

PMID 38211571

Authors

Ranjan Devkota

Jonnell C Small

Kaycee Carbone

Michael A Glass

Amedeo Vetere

Bridget K Wagner

Affiliations

Soon will be listed here.

Abstract

Article Highlights:

References

Heikkila T, Wheatley E, Crighton D, Schroder E, Boakes A, Kaye S . Co-crystal structures of inhibitors with MRCKβ, a key regulator of tumor cell invasion. PLoS One. 2011; 6(9):e24825. PMC: 3176812. DOI: 10.1371/journal.pone.0024825. View

Poitout V, Amyot J, Semache M, Zarrouki B, Hagman D, Fontes G . Glucolipotoxicity of the pancreatic beta cell. Biochim Biophys Acta. 2009; 1801(3):289-98. PMC: 2824006. DOI: 10.1016/j.bbalip.2009.08.006. View

Small J, Joblin-Mills A, Carbone K, Kost-Alimova M, Ayukawa K, Khodier C . Phenotypic Screening for Small Molecules that Protect β-Cells from Glucolipotoxicity. ACS Chem Biol. 2022; 17(5):1131-1142. PMC: 9127801. DOI: 10.1021/acschembio.2c00052. View

DeFronzo R, Ferrannini E, Groop L, Henry R, Herman W, Holst J . Type 2 diabetes mellitus. Nat Rev Dis Primers. 2016; 1:15019. DOI: 10.1038/nrdp.2015.19. View

Feng Y, LoGrasso P, Defert O, Li R . Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential. J Med Chem. 2015; 59(6):2269-300. DOI: 10.1021/acs.jmedchem.5b00683. View

Vogel J, Yin J, Su L, Wang S, Zessis R, Fowler S . A Phenotypic Screen Identifies Calcium Overload as a Key Mechanism of β-Cell Glucolipotoxicity. Diabetes. 2020; 69(5):1032-1041. DOI: 10.2337/db19-0813. View

Doliba N, Liu Q, Li C, Chen P, Liu C, Naji A . Inhibition of cholinergic potentiation of insulin secretion from pancreatic islets by chronic elevation of glucose and fatty acids: Protection by casein kinase 2 inhibitor. Mol Metab. 2017; 6(10):1240-1253. PMC: 5641685. DOI: 10.1016/j.molmet.2017.07.017. View

Lytrivi M, Castell A, Poitout V, Cnop M . Recent Insights Into Mechanisms of β-Cell Lipo- and Glucolipotoxicity in Type 2 Diabetes. J Mol Biol. 2019; 432(5):1514-1534. PMC: 7073302. DOI: 10.1016/j.jmb.2019.09.016. View

Litchfield D . Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J. 2002; 369(Pt 1):1-15. PMC: 1223072. DOI: 10.1042/BJ20021469. View

10.

. 9. Pharmacologic Approaches to Glycemic Treatment: . Diabetes Care. 2020; 44(Suppl 1):S111-S124. DOI: 10.2337/dc21-S009. View

11.

Goldstein D, Gray N, Zarrinkar P . High-throughput kinase profiling as a platform for drug discovery. Nat Rev Drug Discov. 2008; 7(5):391-7. DOI: 10.1038/nrd2541. View

12.

Marselli L, Thorne J, Dahiya S, Sgroi D, Sharma A, Bonner-Weir S . Gene expression profiles of Beta-cell enriched tissue obtained by laser capture microdissection from subjects with type 2 diabetes. PLoS One. 2010; 5(7):e11499. PMC: 2903480. DOI: 10.1371/journal.pone.0011499. View

13.

Siddiqui-Jain A, Drygin D, Streiner N, Chua P, Pierre F, OBrien S . CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010; 70(24):10288-98. DOI: 10.1158/0008-5472.CAN-10-1893. View

14.

Przepiorka D, Le R, Ionan A, Li R, Wang Y, Gudi R . FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy. Clin Cancer Res. 2022; 28(12):2488-2492. PMC: 9197942. DOI: 10.1158/1078-0432.CCR-21-4176. View

15.

Boden G . Obesity, insulin resistance and free fatty acids. Curr Opin Endocrinol Diabetes Obes. 2011; 18(2):139-43. PMC: 3169796. DOI: 10.1097/MED.0b013e3283444b09. View

16.

Tran N, Chun K . ROCK2-Specific Inhibitor KD025 Suppresses Adipocyte Differentiation by Inhibiting Casein Kinase 2. Molecules. 2021; 26(16). PMC: 8401933. DOI: 10.3390/molecules26164747. View

17.

Ocaranza M, Valderas P, Moya J, Gabrielli L, Godoy I, Cordova S . Rho kinase cascade activation in circulating leukocytes in patients with diabetes mellitus type 2. Cardiovasc Diabetol. 2020; 19(1):56. PMC: 7203835. DOI: 10.1186/s12933-020-01027-2. View

18.

Hartmann S, Ridley A, Lutz S . The Function of Rho-Associated Kinases ROCK1 and ROCK2 in the Pathogenesis of Cardiovascular Disease. Front Pharmacol. 2015; 6:276. PMC: 4653301. DOI: 10.3389/fphar.2015.00276. View

19.

Lan Y, Wang Y, Chen H, Lo S, Chen S, Tsai F . Effects of Casein Kinase 2 Alpha 1 Gene Expression on Mice Liver Susceptible to Type 2 Diabetes Mellitus and Obesity. Int J Med Sci. 2020; 17(1):13-20. PMC: 6945564. DOI: 10.7150/ijms.37110. View

20.

Pan P, Shen M, Yu H, Li Y, Li D, Hou T . Advances in the development of Rho-associated protein kinase (ROCK) inhibitors. Drug Discov Today. 2013; 18(23-24):1323-33. DOI: 10.1016/j.drudis.2013.09.010. View